Adagio Medical Chief Business Officer to Assume CFO Duties as Well

Adagio Medical Holdings Inc. Chief Business Officer Deborah Kaster is assuming more responsibility at the company, having been given the duties of chief financial officer (CFO). She succeeds Dan George, who served as interim CFO since April 2025.

“Since joining Adagio, Debbie has made a meaningful impact by driving strategic initiatives and building critical partnerships, both internally and externally, to help position us for growth,” Adagio Medical CEO Todd Usen said. “Expanding her role to include CFO reflects our confidence in Debbie’s deep financial expertise and proven leadership, and ensures alignment between our strategic and financial priorities. We thank Dan for his valuable contributions during this transition period.”

In this dual role as CFO and chief business officer, Kaster will continue to oversee business development, corporate strategy and investor relations while assuming responsibility for the Adagio Medical’s financial operations, including accounting, treasury, and financial planning. Kaster will continue to report to Todd Usen, Chief Executive Officer of Adagio.

“I’m honored to take on the additional role of CFO at this exciting time for Adagio and to continue working with our team to execute on our growth strategy,” Kaster stated. “Integrating our business and financial functions will allow us to move with agility as we focus on bringing our proprietary technologies to patients suffering from ventricular tachycardia and on creating long-term value for shareholders.”

Adagio is a medical device company developing and commercializing products to treat cardiac arrhythmias using its proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on treating ventricular tachycardia (VT) with its purpose-built vCLAS Cryoablation System, which is CE Marked and is currently under evaluation in Adagio Medical’s FULCRUM-VT U.S. IDE Pivotal Study.

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The study’s results will be used to apply for U.S. Food and Drug Administration premarket approval (PMA) for Adagio’s vCLAS Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States.